# Junta clínica — PT-pseudo_47d8b39fd07f (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_47d8b39fd07f",
  "pid": "PT-pseudo_47d8b39fd07f",
  "task": 1,
  "psa": 21.0,
  "age": 60,
  "months": 1,
  "pirads": "3",
  "psad": 0.19,
  "psav": 5.99,
  "psap": 23.5,
  "vol": 112.15,
  "dre": "Normal",
  "bx": "Negative",
  "cspca": 0.4009605,
  "medhx": "Hypertension, COPD",
  "meds": "amlodipine, valsartan, lisinopril, metoprolol, tiotropium, salbutamol PRN",
  "notes": "PSA 21 ng/mL. PI-RADS 3. PSAD 0.19. Prostate volume 112 mL. csPCa 0.40.",
  "pmhx": [
    "Hypertension",
    "COPD"
  ],
  "allergies": [],
  "vitals": {
    "weight": "78 kg",
    "height": "186 cm",
    "bmi": "22.5",
    "bp": "140/82 mmHg",
    "hr": "74 bpm",
    "smoking": "Non-smoker",
    "last_dental": "3 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "22 Jan 2025",
  "enc_ref": "Dr. R. van den Berg (GP)",
  "enc_type": "Re-evaluation - prior negative biopsy",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Rising PSA trajectory combined with intermediate mpMRI findings warrants specialist review following a previously Negative biopsy."
    },
    {
      "s": "History",
      "t": "The patient, a 60-year-old retired baker, initially presented for evaluation of PSA elevation in early 2022, with values climbing to 23.5 ng/mL before stabilizing at 21.0 ng/mL. He reports moderate lower urinary tract symptoms, chiefly nocturia and a weak stream, yielding an IPSS score of 17. A Non-smoker, his past medical history encompasses well-controlled hypertension and mild COPD, currently managed with amlodipine, valsartan, lisinopril, metoprolol, tiotropium, and salbutamol PRN. He maintains an active lifestyle, cycling to work five days weekly, and drinks roughly seven units of alcohol each week. Married, he resides in a multi-generational household with his wife and adult son, a setup he describes as highly supportive. Beyond urinary complaints, he notes stable right knee osteoarthritis that required six physiotherapy sessions last year, alongside occasional mild insomnia. He explicitly denies bone pain, haematuria, or unexplained weight loss. He has previously declined research study participation and wishes to maintain that position."
    },
    {
      "s": "Physical examination",
      "t": "DRE: Normal exam. Prostate texture is symmetrically enlarged, smooth, and firm, lacking discrete nodules or asymmetry. General assessment remains unremarkable, recording blood pressure at 140/82 mmHg and heart rate at 74 bpm, with no peripheral lymphadenopathy or abdominal masses detected."
    }
  ],
  "occupation": "retired baker",
  "marital": "Married",
  "living": "Lives with adult child (multi-generational household)",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "GP practice nurse — flu vaccination",
    "Physiotherapy — lower back, six sessions",
    "Radiology — chest X-ray (routine)"
  ],
  "alcohol": "7 units / week",
  "exercise": "Cycling 5x/week (commuter)",
  "ipss": "IPSS score: 17/35 (moderate LUTS)",
  "admin": "Patient declined research participation previously; respect for AS-related trials.",
  "mri_hospital": "LUMC (Leiden)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_47d8b39fd07f
Task: 1

Encounter: Urology - outpatient on 22 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 60-year-old male
  - PSA: 21.0 ng/mL
  - mpMRI — PI-RADS score: 3 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.19 ng/mL²
  - PSA velocity: 5.99 ng/mL/yr
  - Prior PSA: 23.5 ng/mL
  - Prostate volume: 112.15 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.4009605 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, COPD
  - Problem list / PMHx: Hypertension, COPD
  - Current medication: amlodipine, valsartan, lisinopril, metoprolol, tiotropium, salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 21 ng/mL. PI-RADS 3. PSAD 0.19. Prostate volume 112 mL. csPCa 0.40.

Vitals: weight 78 kg, height 186 cm, BMI 22.5, BP 140/82 mmHg, HR 74 bpm. Smoking: Non-smoker.

Chief complaint: Rising PSA trajectory combined with intermediate mpMRI findings warrants specialist review following a previously Negative biopsy.

History: The patient, a 60-year-old retired baker, initially presented for evaluation of PSA elevation in early 2022, with values climbing to 23.5 ng/mL before stabilizing at 21.0 ng/mL. He reports moderate lower urinary tract symptoms, chiefly nocturia and a weak stream, yielding an IPSS score of 17. A Non-smoker, his past medical history encompasses well-controlled hypertension and mild COPD, currently managed with amlodipine, valsartan, lisinopril, metoprolol, tiotropium, and salbutamol PRN. He maintains an active lifestyle, cycling to work five days weekly, and drinks roughly seven units of alcohol each week. Married, he resides in a multi-generational household with his wife and adult son, a setup he describes as highly supportive. Beyond urinary complaints, he notes stable right knee osteoarthritis that required six physiotherapy sessions last year, alongside occasional mild insomnia. He explicitly denies bone pain, haematuria, or unexplained weight loss. He has previously declined research study participation and wishes to maintain that position.

Physical examination: DRE: Normal exam. Prostate texture is symmetrically enlarged, smooth, and firm, lacking discrete nodules or asymmetry. General assessment remains unremarkable, recording blood pressure at 140/82 mmHg and heart rate at 74 bpm, with no peripheral lymphadenopathy or abdominal masses detected.

Patient info: retired baker; Married; Lives with adult child (multi-generational household).
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 7 units / week; exercise Cycling 5x/week (commuter); IPSS score: 17/35 (moderate LUTS).

Recent other appointments: GP practice nurse — flu vaccination; Physiotherapy — lower back, six sessions; Radiology — chest X-ray (routine).
Admin: Patient declined research participation previously; respect for AS-related trials.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.31
  uncertainty  +/- 0.16 epistemic (95% band 0.00-0.63); among patients I cannot tell apart the outcome was 0.89 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior negative biopsy. My criterion answers DEFER.

The criterion: repeat, targeted, when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for an unchanged PI-RADS 3 or lower picture. In the labelled series this criterion matched the reading urologist in 16 of 18 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 17 labelled men in this same situation (Negative prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.67: PI-RADS 3, PSA 7.4, PSAD 0.16, age 61, DRE Normal -> DEFER (uncertain). He wrote: "At what PSA level the prior biopsy was taken? If PIRADS 3 is new and PSA is significantly rising since last biopsy I would consider repeat biopsy an option"
  2. distance 2.54: PI-RADS 4, PSA 9.2, PSAD 0.16, age 54, DRE Normal -> BIOPSY (uncertain). He wrote: "Again earlier MRI report is missing, If new PRADS 4 lesion biopsy is needed as PSA is rising as well"
  3. distance 2.55: PI-RADS 4, PSA 8.8, PSAD 0.09, age 52, DRE Normal -> BIOPSY (clear). He wrote: "P4 in 52 Y old patient."

PRECEDENT: BIOPSY (weighted vote 0.57 for biopsy). Distance-weighted precedent is fair here (0.78 leave-one-out).

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 17 labelled traces in this situation (Negative prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=decisive, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines suggest that a PI-RADS score of 3 is used to trigger a biopsy, but the decision is risk-adapted based on other factors. The guideline states, "a PI-RADS threshold of $\ge 3$ is used to trigger biopsy [135, 226, 264, 375], at the cost of missing a small number of mainly ISUP GG 2 cancers, especially in biopsy-naïve patients or in highly selected populations with high prevalence of csPCa (in which the MRI NPV decreases) [372, 472]."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, your suggestion of no biopsy is not decisively supported by the guideline, as the guideline indicates that a PI-RADS $\ge 3$ triggers biopsy, and the decision must be risk-adapted. EXPERT-COHORT, your criterion that defers based on an unchanged PI-RADS 3 is not explicitly supported by the guideline, which suggests that a PI-RADS $\ge 3$ mandates biopsy.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the patient's history of rising PSA and previous negative biopsy means the guideline requires assessing risk factors to determine if a repeat biopsy is warranted.
radiology_report - the MRI findings, specifically the PI-RADS 3 score, is the primary factor that the guideline uses to trigger the initial decision.
psa_trend - the PSA velocity of 5.99 ng/mL/yr must be considered in conjunction with the PI-RADS score to assess risk.
laboratory_results - the PSA density of 0.19 ng/mL² is a factor in risk stratification according to the guideline.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on whether the PI-RADS 3 finding, combined with the rising PSA velocity, warrants a repeat biopsy according to the EAU guidelines.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What are the specific details regarding the lesion size, zone, and extraprostatic extension?
  psa_trend (get_psa_trend) -> How should the PSA velocity of 5.99 ng/mL/yr be interpreted in conjunction with the PI-RADS 3 score?
  previous_notes (get_previous_notes) -> What is the GRADE (Gleason/ISUP) of the prior negative biopsy, and is there an existing surveillance protocol?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the GRADE of the prior negative biopsy mentioned in the previous notes?
  Q2. Given the PI-RADS 3 score and the PSA velocity of 5.99 ng/mL/yr, what risk stratification factors should be prioritized according to the EAU guidelines?

On the plan itself: The moderator asked for laboratory_results, which the reading urologist does not open in this situation; dropped — every reveal beyond his is scored against us.

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The specific details regarding the lesion size, zone, and extraprostatic extension are: "T2 sequences show a 12 mm focus in the right mid-gland peripheral zone, showing intermediate signal with subtly indistinct borders. DWI indicates moderate restriction alongside moderately lowered ADC values. DCE highlights focal early enhancement. Extracapsular extension is absent."
psa_trend
The PSA velocity of 5.99 ng/mL/yr should be interpreted in conjunction with the PI-RADS 3 score to assess risk.
previous_notes
The GRADE (Gleason/ISUP) of the prior negative biopsy is not recorded, and there is no existing surveillance protocol mentioned.

WHAT I DID NOT OPEN
laboratory_results, because the reading urologist does not open in this situation.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 3 finding is a factor that the guideline uses to trigger the initial decision.
PSA velocity of 5.99 ng/mL/yr indicates a rising trend that warrants risk assessment.
AGAINST sampling this patient now
Prior negative biopsy means a repeat biopsy is not automatically indicated.
No existing surveillance protocol is noted in the previous notes.

WHERE THIS LEANS
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 21.00 ng/mL over 4 points spanning 34 months; velocity +7.18 ng/mL per year; doubling time about 11 months.
PROJECTION at 6 months: 24.0 ng/mL, conformal 95% band 6.9-83.7.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.44
  uncertainty  +/- 0.15 epistemic (95% band 0.15-0.74), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.31  ('supports' tier; weight 2.0)
  EXPERT-FUSION      DEFER, p(biopsy)=0.44  ('discuss' tier, fusion_nolab; weight 1.5)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.57  (k=3 precedents; does not vote)
  EXPERT-COHORT      DEFER  (rule pirads_le_3; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (pirads_le_3) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 16 of 18 labelled cases in exactly this situation (prior negative biopsy).
Dissenting on the board: EXPERT-LIBRARY. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: clear. Weights it expects: bx=decisive, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved—radiology_report, psa_trend, and previous_notes—address the moderator's questions to the extent that they provide information regarding the PI-RADS 3 finding, the PSA velocity, and the prior biopsy status.

ALIGNMENT WITH THE PANEL
The retrieved evidence supports the PANEL-PROTOCOL's answer of NO BIOPSY, as the cohort criterion (PI-RADS $\le 3$) fired, which is explicitly documented in the protocol.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the GRADE of the prior negative biopsy mentioned in the previous notes? This remains unanswered, as the registrar reported that the GRADE was not recorded.
Q2. Given the PI-RADS 3 score and the PSA velocity of 5.99 ng/mL/yr, what risk stratification factors should be prioritized according to the EAU guidelines? The retrieved documents mention these factors but do not provide a synthesized answer based on the EAU guidelines.

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS 3 score is highly relevant as it is the primary factor triggering the cohort criterion that led to the panel's decision. The PSA velocity of 5.99 ng/mL/yr is important as it indicates a rising trend requiring risk assessment per the EAU guidelines.

MY SUGGESTION TO THE CHAIR
I suggest deferring the decision, as the retrieved information is insufficient to definitively answer the open questions, particularly regarding the GRADE of the prior biopsy and the specific risk stratification required by the EAU guidelines for a PI-RADS 3 finding with a rising PSA velocity.

VERDICT: not-ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

60y/o, PSA 21.0, PSAD 0.19, PI-RADS 3, prior negative biopsy. PI-RADS 3 without rising PSAD does not justify repeat biopsy given prior negative result. Re-imaging in one year is an alternative plan if lesion changes.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
